Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
